Revolo Biotherapeutics

Revolo Biotherapeutics is developing revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases. Its two drug candidates, 1805 and 1104, a protein and a peptide respectively, reset the immune system by preventing the chronic pro-inflammatory immune response that results in autoimmune or allergic disease. 1805 is a modified analogue of a key molecule in immune function and is in clinical development for moderate-to-severe rheumatoid arthritis and non-infectious uveitis. 1104 is a peptide derived from a natural immune-regulatory protein and is in clinical development for patients with eosinophilic esophagitis (EoE) and allergic disease. The disease-agnostic mechanism of action of Revolo Biotherapeutics assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases. Visit www.revolobio.com to learn more